- 期刊
雙重抗血小板藥物之新希望？淺談THALES試驗
Dual Antiplatelet Therapy in Acute Stroke: A New Hope?
並列摘要
Since the positive results of CHANCE and POINT trials, early initiation of dual antiplatelet therapy comprised of clopidogrel and aspirin, administered for 10 to 21 days, has become a standard treatment protocol for patients with mild acute ischemic stroke or high risk transient ischemic attack. The recently published THALES trial demonstrated that combining ticagrelor, a direct acting platelet P2Y12 receptor antagonist, and aspirin for 30 days can also prevent at least 17% of early recurrent stroke in the similar patient group, but increase major bleeding risk up to four times compared with standard treatment. A ticagrelor-based dual antiplatelet therapy may provide an alternative option to those who are clopidogrel poor-respondent; nevertheless, the concern of higher bleeding risk may preclude its universal usage. Further clinical trials comparing clopidogrel-based and ticagrelor-based dual antiplatelet therapy may help clarifying direct evidence on which combination regimen is favored.
延伸閱讀
- 林嘉慶（2008）。評估長期使用雙重抗血小板凝集藥物在低危險性急性冠心症的療效與此疾病的相關危險因子探討- 以高屏地區為例〔碩士論文，高雄醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0011-0506200814332500
- 林佩津（2010）。以實證醫學觀點探討質子幫浦抑制劑與抗組織胺-2 接受體拮抗劑預防重症病人壓力性潰瘍之臨床效果及經濟評估〔博士論文，高雄醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0011-3008201014315100
- 陳惠明、林耀東、陳惠文（2009）。抗血小板藥物和Cilostazol在週邊動脈阻塞疾病的應用。臺灣醫界，52(9)，12-14。https://doi.org/10.30044/TMJ.200909.0003
- 葉馨喬（2019）。Dual Antiplatelet Therapy for Minor Ischemic Stroke or Transient Ischemic Attack。台灣醫學，23(6)，728-732。https://doi.org/10.6320/FJM.201911_23(6).0005
- 林欣儀、湯頌君、鄭建興（2020）。Management of Antiplatelets-Associated Intracerebral Hemorrhage。台灣中風醫誌，2(1)，35-42。https://doi.org/10.6318/FJS.202003_2(1).0003